Neuroprotection from Delayed Postischemic Administration of a Metalloporphyrin Catalytic Antioxidant

Reactive oxygen species contribute to ischemic brain injury. This study examined whether the porphyrin catalytic antioxidant manganese (III) meso-tetrakis (N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP5+) reduces oxidative stress and improves outcome from experimental cerebral ischemia. Rats that were subjected to 90 min focal ischemia and 7 d recovery were given MnTE-2-PyP5+ (or vehicle) intracerebroventricularly 60 min before ischemia, or 5 or 90 min or 6 or 12 hr after reperfusion. Biomarkers of brain oxidative stress were measured at 4 hr after postischemic treatment (5 min or 6 hr). MnTE-2-PyP5+, given 60 min before ischemia, improved neurologic scores and reduced total infarct size by 70%. MnTE-2-PyP5+, given 5 or 90 min after reperfusion, reduced infarct size by 70–77% and had no effect on temperature. MnTE-2-PyP5+ treatment 6 hr after ischemia reduced total infarct volume by 54% (vehicle, 131 ± 60 mm3; MnTE-2-PyP5+, 300 ng, 60 ± 68 mm3). Protection was observed in both cortex and caudoputamen, and neurologic scores were improved. No MnTE-2-PyP5+ effect was observed if it was given 12 hr after ischemia. MnTE-2-PyP5+ prevented mitochondrial aconitase inactivation and reduced 8-hydroxy-2′-deoxyguanosine formation when it was given 5 min or 6 hr after ischemia. In mice, MnTE-2-PyP5+ reduced infarct size and improved neurologic scores when it was given intravenously 5 min after ischemia. There was no effect of 150 or 300 ng of MnTE-2-PyP5+ pretreatment on selective neuronal necrosis resulting from 10 min forebrain ischemia and 5 d recovery in rats. Administration of a metalloporphyrin catalytic antioxidant had marked neuroprotective effects against focal ischemic insults when it was given up to 6 hr after ischemia. This was associated with decreased postischemic superoxide-mediated oxidative stress.